NCT02936037: A reported trial by MedDay Pharmaceuticals SA
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02936037 |
|---|---|
| Title | Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Dec. 31, 2016 |
| Completion date | Nov. 15, 2019 |
| Required reporting date | Nov. 14, 2020, midnight |
| Actual reporting date | Oct. 29, 2020 |
| Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
| Days late | None |